Composition for reducing egg allergen activity

Abstract

To provide a composition for reducing the activity of egg allergen.SOLUTION: A composition for reducing the activity of egg allergen contains cetylpyridinium chloride and / or benzalkonium chloride.SELECTED DRAWING: None

Description

[Technical Field]

[0001] The present disclosure relates to a composition for reducing egg allergen activity, etc. [Background technology]

[0002] In recent years, many allergic diseases, such as atopic dermatitis, bronchial asthma, and allergic rhinitis, have become a problem. Allergic diseases can be caused by, for example, ingesting foods containing allergens (food allergies), or by allergens present in the environment (e.g., the air or a home). More specifically, allergic diseases can be caused by, for example, inhaling allergens present in the air or touching allergens present on objects in a living space (e.g., doors or walls). For this reason, it is considered important to remove or reduce the activity of allergens in the environment. To date, in order to reduce the activity of environmental allergens, preparations have been developed that have the effect of reducing the activity of, for example, mite allergens and pollen allergens (Patent Documents 1 to 5). However, there has been little awareness that food allergens exist in the environment, and there have been few reports on ingredients that have the effect of reducing the activity of egg allergens, which are one type of food allergen. Therefore, there has been a need for a method to reduce the activity of egg allergens (especially egg allergens present in the environment). [Prior art documents] [Patent documents]

[0003] [Patent Document 1] Patent No. 6533853 [Patent Document 2] Patent No. 5574409 [Patent Document 3] Patent No. 4157692 [Patent Document 4] International Publication No. 2009 / 044648 [Patent Document 5] Patent No. 6721040 Summary of the Invention [Problem to be solved by the invention]

[0004] An objective of the present disclosure is to provide a composition that reduces the activity of egg allergens (particularly egg allergens present in the environment). [Means for solving the problem]

[0005] The present inventors have found that cetylpyridinium chloride and benzalkonium chloride reduce the activity of egg allergens and have made further improvements.

[0006] The present disclosure encompasses, for example, the subject matter described in the following sections: Section 1. A composition for reducing egg allergen activity, comprising cetylpyridinium chloride and / or benzalkonium chloride. Section 2. Item 1. The composition according to Item 1, containing cetylpyridinium chloride and / or benzalkonium chloride in a total amount of 0.01% by mass or more. Section 3. Item 3. The composition according to Item 1 or 2, wherein the egg allergen is an egg white allergen. Section 4. Item 3. The composition according to Item 1 or 2, wherein the egg allergen is ovalbumin. Section 5. Item 5. The composition according to any one of Items 1 to 4, wherein the egg allergen is an environmental egg allergen. [Effects of the Invention]

[0007] The activity of egg allergens can be reduced. DETAILED DESCRIPTION OF THE INVENTION

[0008] Each embodiment included in the present disclosure will be described in further detail below. The compositions encompassed by the present disclosure include cetylpyridinium chloride (CPC) and / or benzalkonium chloride, and may be referred to herein as "compositions of the present disclosure."

[0009] The content of cetylpyridinium chloride in the composition of the present disclosure is not particularly limited, as long as it can reduce the activity of egg allergens. For example, it can be 0.01% by mass or more, and the upper limit is not particularly limited, as long as it can reduce the activity of egg allergens. The upper or lower limit of this range may be, for example, approximately 0.015, 0.02, 0.025, 0.03, 0.04, 0.05, 0.1, 0.2, 0.4, 0.6, 0.8, 1, 2, 3, 4, 5, 10, 20, or 30% by mass. More specifically, it may be, for example, approximately 0.01 to 5% by mass, approximately 0.01 to 1% by mass, approximately 0.02 to 0.2% by mass, or approximately 0.02 to 0.1% by mass.

[0010] The content of benzalkonium chloride in the composition of the present disclosure is not particularly limited as long as it can reduce the activity of egg allergens. For example, it can be 0.01% by mass or more, and the upper limit is not particularly limited as long as it can reduce the activity of egg allergens. The upper or lower limit of this range may be, for example, approximately 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 10, 20, or 30% by mass. More specifically, it may be, for example, approximately 0.01 to 5% by mass, approximately 0.01 to 1% by mass, approximately 0.03 to 0.2% by mass, or approximately 0.03 to 0.1% by mass.

[0011] The total content of cetylpyridinium chloride and benzalkonium chloride contained in the composition of the present disclosure is not particularly limited, as long as it can reduce the activity of egg allergens. For example, it can be 0.01% by mass or more, and the upper limit is not particularly limited, as long as it can reduce the activity of egg allergens. The upper or lower limit of this range may be, for example, approximately 0.015, 0.02, 0.025, 0.03, 0.04, 0.05, 0.1, 0.2, 0.4, 0.6, 0.8, 1, 2, 3, 4, 5, 10, 20, 30, 40, or 50% by mass. More specifically, it may be, for example, approximately 0.01 to 5% by mass, approximately 0.01 to 1% by mass, or approximately 0.02 to 0.1% by mass.

[0012] As shown in the Examples below, the composition of the present disclosure can reduce the activity of egg allergens. Examples of egg allergens include egg white allergens and egg yolk allergens. Of these, egg white allergens are preferred. Examples of egg white allergens include ovalbumin, ovomucoid, lysozyme, ovotransferrin, and the like. Of these, ovalbumin is preferred. The target egg allergen may be a single type or a combination of two or more types. Furthermore, it has been reported in recent years that egg allergens are present in the environment, and therefore the composition of the present disclosure can be suitably used for reducing the activity of egg allergens in the environment.

[0013] The composition of the present disclosure contains cetylpyridinium chloride and / or benzalkonium chloride, and may further contain other ingredients. Examples of such other ingredients include solvents, carriers, dispersants, emulsifiers, buffers, stabilizers, excipients, binders, disintegrants, lubricants, thickeners, surfactants, antioxidants, preservatives, antiseptics, disinfectants, coating agents, colorants, fragrances, pH adjusters, and other antiallergenic ingredients. These ingredients may be used alone or in combination of two or more.

[0014] Examples of the solvent include water; alcohols such as methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, sec-butanol, tertiary butanol, and n-hexanol; ethylene glycol, diethylene glycol, triethylene glycol, tetraethylene glycol, polyoxyethylene glycol 200, polyoxyethylene glycol 400, propylene glycol, dipropylene glycol, ethylene glycol monomethyl ether, ethylene glycol monoethyl ether, ethylene glycol monobutyl ether, ethylene glycol monohexyl ether, ethylene glycol mono-2-ethylhexyl ether, and diethylene glycol monoethyl ether. Examples of suitable solvents include glycol ethers such as propylene glycol monomethyl ether, diethylene glycol monobutyl ether, diethylene glycol monohexyl ether, diethylene glycol mono-2-ethylhexyl ether, triethylene glycol monobutyl ether, propylene glycol monomethyl ether, propylene glycol monoethyl ether, propylene glycol mono-n-propyl ether, propylene glycol mono-n-butyl ether, propylene glycol mono-n-butyl ether, dipropylene glycol monomethyl ether, dipropylene glycol monoethyl ether, tripropylene glycol monomethyl ether, 3-methoxybutanol, and 3-methyl-3-methoxybutanol. Among these, water or alcohols are preferred. These solvents may be used alone or in combination of two or more.

[0015] The composition of the present disclosure can be prepared by combining cetylpyridinium chloride and / or benzalkonium chloride with other ingredients as needed in a conventional manner.

[0016] The form of the composition of the present invention is not particularly limited. For example, it may be in a liquid form (e.g., solution, suspension, etc.), paste form, gel form, cream form, or solid form (e.g., powder, granules, etc.). Among these, a liquid form is preferred.

[0017] In recent years, it has been reported that egg allergens are present in the environment. Therefore, the composition of the present invention can be used by, for example, attaching it to an object in which egg allergens may be present by spraying, applying, immersing, or the like. Examples of objects in which egg allergens may be present include, but are not limited to, clothing, carpets, sofas, wallpaper, curtains and other interior items, bedding such as futon covers, futon batting, sheets, pillowcases, mats and other bedding, car seats, car mats, automobile parts such as ceiling materials and floor materials, stuffed toys, wet cleaning wipes, masks, filter materials, vacuum cleaner dust bags and other fibers and textile products. The composition of the present disclosure can also be added to detergents, fabric softeners, and the like used in laundry.

[0018] The effect of the composition of the present disclosure in reducing the activity of egg allergens (more specifically, egg allergens in the environment) was confirmed for the first time by the evaluation method described in the Examples below (more specifically, a method in which egg allergens are reacted with anti-egg allergen IgE antibodies in serum that react to egg allergens and are collected from the blood of allergic patients).

[0019] It should be noted that in this specification, the term "comprising" includes "consisting essentially of" and "consisting of." Furthermore, the present disclosure encompasses all arbitrary combinations of the constituent elements described in this specification.

[0020] Furthermore, the various characteristics (properties, structures, functions, etc.) described in each embodiment of the present disclosure above may be combined in any way to specify the subject matter encompassed by the present disclosure, i.e., the present disclosure encompasses all subject matter consisting of any combination of the combinable characteristics described herein. [Example]

[0021] The contents of the present disclosure will be specifically explained using the following examples. However, the present disclosure is not limited to these examples. In the following, unless otherwise specified, experiments were performed under atmospheric pressure and room temperature conditions. Furthermore, unless otherwise specified, "%" means "% by mass." Furthermore, the blending amount of each component listed in each table is also expressed in "% by mass" unless otherwise specified.

[0022] The egg allergen inactivation (activity reduction) rate was measured using a competitive ELISA. Egg allergen (OVA) was prepared at 1 μg / mL, added to an ELISA plate, and left to stand overnight at 4°C for immobilization (OVA solid-phase plate). OVA and drug were mixed at a 9:1 ratio to prepare an allergen concentration of 10 μg / mL, and reacted overnight at 4°C (allergen reaction solution). A control was prepared using purified water instead of drug. The resulting allergen reaction solution and anti-OVA IgE antibodies in serum recovered from allergic patients that react with OVA were added to the OVA solid-phase plate for a competitive reaction. The anti-OVA IgE antibodies in serum that bound to the OVA immobilized on the plate were allowed to bind with enzyme-labeled anti-IgE antibodies, and the luminescence of the substrate was detected. Since anti-OVA IgE antibodies in serum do not bind to inactivated OVA, we determined that the more antibodies in serum that bind to OVA immobilized on the plate (stronger luminescence intensity), the greater the inactivation effect.

[0023] The drugs used were 0.1% aqueous solution of cetylpyridinium chloride (CPC), 0.05% aqueous solution of CPC, 0.025% aqueous solution of CPC, 0.01% aqueous solution of CPC, 0.1% aqueous solution of benzalkonium chloride, 0.05% aqueous solution of benzalkonium chloride, 0.025% aqueous solution of benzalkonium chloride, and 0.01% aqueous solution of tannic acid. Note that, because the drug turns brown when the amount of tannic acid is increased, a concentration of 0.01% was selected, which does not cause browning.

[0024] The concentration of OVA that exhibits 50% of the control fluorescence intensity is defined as the 50% inhibition concentration (IC 50 ) and the IC of the drug 50The relative IgE binding titer and allergen inactivation rate were calculated using the following formula. Inhibition (%) = (control fluorescence intensity - drug fluorescence intensity) / (control fluorescence intensity - blank fluorescence intensity) x 100 IgE binding relative titer = control IC 50 / Drug IC 50 Inactivation rate (%) = (1 - relative IgE binding titer) x 100 The results are shown in Table 1.

[0025] [Table 1]

[0026] As shown in Table 1, it was confirmed that cetylpyridinium chloride and benzalkonium chloride have a high activity-reducing effect on OVA. In addition, it was confirmed that tannic acid, which is known to have an effect of reducing allergen activity against mites and cedar pollen, has almost no activity-reducing effect on OVA.

Claims

1. A composition for reducing egg allergen activity, comprising cetylpyridinium chloride and / or benzalkonium chloride, The composition, wherein the egg allergen is an environmental egg allergen.

2. The composition according to claim 1, containing cetylpyridinium chloride and / or benzalkonium chloride in a total amount of 0.01% by mass or more.

3. The composition of claim 1 or 2, wherein the egg allergen is an egg white allergen.

4. 3. The composition of claim 1, wherein the egg allergen is ovalbumin.

5. A composition described in claim 1 or 2 for use by attaching it to an object in which egg allergens may be present.

Images